The licensing part is music to my ears. I’m glad Leo is planning to license each indication because there’s no way he can get full value by selling the platform right now.

Which BP with oncology pipeline wouldn’t want to add B-OM? Not only they could make money in a $1B market with little competition, they could also sell more cancer drugs because patients don’t need to discontinue their treatments due to severe OM.